Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merrimack Pharmaceuticals and CTCA Partner in Multifaceted Collaboration

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
Partnership to advance translational research and individualized treatment.

Merrimack Pharmaceuticals, Inc. and the Cancer Treatment Centers of America® (CTCA) have announced that they have formed a unique and wide ranging partnership to advance their long-term vision of individualized treatment - where diagnosis and therapy is guided by an in-depth understanding of the underlying mechanism of a patient’s disease.

The collaboration encompasses research on diagnostics based on a network signaling approach to analyzing patients’ tumors as well as clinical trial research.

For the diagnostic research, CTCA will contribute archived tumor biopsies from their extensive tumor databank as well as prospectively collected tumor samples.

These samples will be analyzed using Merrimack’s Network Biology approach to identifying the network signaling that drives cancer growth with the goal of understanding each patient’s cancer at the molecular level.

Many of CTCA’s patients are battling advanced cancer and have received many prior lines of therapy.

This makes CTCA’s tumor archive particularly unique as they offer an opportunity for Merrimack to explore how the molecular characteristics of a tumor change as a result of therapy.

This joint effort eventually could lead to the identification of novel companion diagnostics to guide treatment decisions.

“Every day, experts at CTCA provide personalized care to advanced and late-stage cancer patients. This partnership with Merrimack supports our goal to give every patient an individually focused treatment plan, using innovative technologies and tools to help fight their cancer and improve their quality of life,” said Maurie Markman, M.D., Senior Vice President of Clinical Affairs & National Director of Medical Oncology at CTCA.

Markman continued, “We believe that the innovations that come from this partnership could help provide the right treatment for every patient’s unique biology.”

“Access to CTCA’s tumor samples greatly enhances the speed and scope of the research we are doing to understand the complexity of cancer cells and to characterize what their growth is dependent upon,” says Robert Mulroy, CEO of Merrimack Pharmaceuticals.

Mulroy continued, “CTCA is a great example of a forward-looking institution trying to change the face of cancer care. This collaboration represents the future of individualized treatment where a hospital and a biopharmaceutical company work together on research, which we hope will ultimately result in much better treatment for cancer patients.”

The collaboration also encompasses clinical research. Merrimack will collaborate with CTCA investigators to take advantage of the rich clinical expertise at CTCA through participation in and collaboration on clinical studies of Merrimack therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Rapidly Generating Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
New Mechanism of Tuberculosis Infection
Researchers have identified a new infection mechanism of tuberculosis that could lead to a new therapeutic angle.
Modelling ALS Requires ‘Aged’ Stem Cells
Research suggests engineered cells are too ‘young’ to accurately model ALS and should be 'aged' to speed progress toward finding potential treatments.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
HIV Hides No Longer
Researchers are working to create proteins that clear HIV-infected cells in order to eliminate latent infection and dormancy.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!